Sarepta Therapeutics (SRPT) Expected to Announce Quarterly Earnings on Wednesday

Sarepta Therapeutics (NASDAQ:SRPT) is expected to be announcing its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect Sarepta Therapeutics to post earnings of ($0.87) per share and revenue of $390.9530 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 4:30 PM ET.

Sarepta Therapeutics Stock Up 0.5%

Shares of NASDAQ SRPT opened at $17.88 on Wednesday. The business has a 50-day moving average of $20.94 and a two-hundred day moving average of $20.20. Sarepta Therapeutics has a 1 year low of $10.41 and a 1 year high of $110.00. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.95 and a quick ratio of 1.79. The company has a market capitalization of $1.87 billion, a price-to-earnings ratio of -5.94, a price-to-earnings-growth ratio of 0.45 and a beta of 0.39.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, COO Ian Michael Estepan sold 13,187 shares of the stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total value of $294,201.97. Following the completion of the sale, the chief operating officer directly owned 193,300 shares in the company, valued at $4,312,523. This represents a 6.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 7.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in SRPT. Schonfeld Strategic Advisors LLC boosted its position in Sarepta Therapeutics by 3.8% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 24,620 shares of the biotechnology company’s stock valued at $530,000 after buying an additional 896 shares in the last quarter. AQR Capital Management LLC boosted its position in Sarepta Therapeutics by 454.6% during the 4th quarter. AQR Capital Management LLC now owns 7,796,535 shares of the biotechnology company’s stock worth $167,781,000 after buying an additional 6,390,860 shares during the period. Trexquant Investment LP grew its holdings in Sarepta Therapeutics by 11.0% during the 4th quarter. Trexquant Investment LP now owns 178,343 shares of the biotechnology company’s stock worth $3,838,000 after acquiring an additional 17,681 shares during the last quarter. Quantitative Investment Management LLC acquired a new position in Sarepta Therapeutics in the 4th quarter valued at approximately $1,370,000. Finally, California State Teachers Retirement System increased its position in Sarepta Therapeutics by 15.1% in the 4th quarter. California State Teachers Retirement System now owns 94,545 shares of the biotechnology company’s stock valued at $2,035,000 after acquiring an additional 12,404 shares during the period. 86.68% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

SRPT has been the topic of several analyst reports. Weiss Ratings restated a “sell (d)” rating on shares of Sarepta Therapeutics in a report on Monday, December 29th. Wells Fargo & Company lowered their target price on shares of Sarepta Therapeutics from $50.00 to $45.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Guggenheim reduced their price objective on Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Wedbush lifted their target price on Sarepta Therapeutics from $32.00 to $34.00 and gave the stock an “outperform” rating in a report on Friday, January 23rd. Finally, Royal Bank Of Canada boosted their price target on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the company a “sector perform” rating in a report on Thursday, January 8th. Nine investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have issued a Sell rating to the stock. According to data from MarketBeat.com, Sarepta Therapeutics currently has a consensus rating of “Hold” and an average price target of $33.84.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.